Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that was approved for postmenopausal osteoporosis in 2019 and ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but ...

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the approval of AVT03, a proposed biosimilar of Amgen’s AMGN Prolia ...

In addition, Fresenius’ operating company has reached a global settlement with Amgen concerning its denosumab biosimilars. “We are pleased to have reached a global settlement with Amgen for ...